Put companies on watchlist
PharmaSGP Holding SE
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

PharmaSGP Holding SE · ISIN: DE000A2P4LJ5 · EQS - adhoc news (66 News)
Country: Germany · Primary market: Germany · EQS NID: 2022283
05 November 2024 10:02AM

Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer


EQS-Ad-hoc: PharmaSGP Holding SE / Key word(s): Personnel
PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer

05-Nov-2024 / 10:02 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer

Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January 1, 2025. This was decided by the Supervisory Board today. Peter Gerckens succeeds Natalie Weigand in this position. She informed the Supervisory Board today that she has decided not to extend her contract, which expires at the end of the year. However, Natalie Weigand will remain associated with the company in an advisory role after her departure.

*    *    *
 

Contact

PharmaSGP Holding SE
Claudius Krause | Jakob Hafer (cometis AG)
Lochhamer Schlag 1
82166 Gräfelfing | Germany
Phone: +49 611 205855-0
E-Mail: ir@pharmasgp.com



End of Inside Information

05-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: PharmaSGP Holding SE
Lochhamer Schlag 1
82166 Gräfelfing
Germany
E-mail: ir@pharmasgp.com
Internet: https://pharmasgp.com
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange
EQS News ID: 2022283

 
End of Announcement EQS News Service

2022283  05-Nov-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2022283&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - PharmaSGP Holding SE
Smart analysis and research tools can be found here.
MIC: XFRA
Power-Shortcuts

PharmaSGP Holding SE

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.